Vivos Therapeutics, Inc., a pioneering medical technology company based in Highlands Ranch, United States, has recently made headlines with its third-quarter earnings report for 2025. Operating within the Health Care sector, Vivos Therapeutics is dedicated to developing cutting-edge technology aimed at treating sleep disordered breathing and obstructive sleep apnea. The company’s mission is to transform the landscape of sleep-related respiratory disorder treatments, offering innovative solutions that significantly enhance patients’ quality of life.
In its latest earnings release dated November 19, 2025, Vivos Therapeutics reported a notable increase in revenue, a development that has captured the attention of investors and market analysts alike. This positive financial performance is reflected in the company’s stock, which closed at $2.16 on the most recent trading session. Over the past year, Vivos Therapeutics’ stock has experienced fluctuations, with a low of $1.98 on December 2, 2025, and a peak of $7.95 on July 10, 2025. These figures indicate a level of volatility that is relatively modest when compared to its industry peers.
Despite the recent uptick in revenue, Vivos Therapeutics continues to grapple with operating losses, as evidenced by its negative price-to-earnings ratio of –1.13. This metric suggests that the company is currently not generating profits, a situation that is not uncommon for firms heavily invested in research and development within the medical technology sector. However, the price-to-book ratio of 7.3481 indicates that the market values the company at more than seven times its book value, underscoring investor confidence in its long-term potential and strategic direction.
The recent earnings announcement has exerted upward pressure on Vivos Therapeutics’ stock, although the broader market consensus remains cautious. Investors are weighing the company’s innovative approach and potential for growth against the backdrop of its current financial performance. As Vivos Therapeutics continues to serve its customer base exclusively in the United States, its focus remains on advancing its technology and expanding its impact on the treatment of sleep-related respiratory disorders.
For those interested in learning more about Vivos Therapeutics and its offerings, further information can be accessed through their website at www.vivoslife.com . As the company navigates the challenges and opportunities within the Health Care sector, its commitment to revolutionizing sleep disorder treatments remains steadfast, promising a future where patients can enjoy improved quality of life through innovative medical solutions.
